The cucurbitacins E, D and I: Investigation of their cytotoxicity toward human chondrosarcoma SW 1353 cell line and their biotransformation in man liver
Highlights
► Cucurbitacins I, D and E cytotoxicity toward chondrosarcoma was investigated. ► All cucurbitacins showed a very strong cytotoxicity and induced apoptosis. ► Cucurbitacins biotransformation in vitro in human liver was investigated. ► Cucurbitacin were glucuronidated by several UGTs isoforms at a very low extent. ► Cucurbitacin E was hydrolyzed by microsomal esterases leading to cucurbitacin I.
Introduction
Cucurbitacins are a family of highly oxygenated triterpenoids characterized by tetracyclic cucurbitane nucleus skeleton: the 19-(10 → 9β)-abeo-10α-lanost-5-ene (Chen et al., 2005, Seger et al., 2005). They are natural compounds found mainly in Cucurbitaceae and in large varieties of plants families (Chen et al., 2005, Dirr et al., 1986). Cucurbitacin synthesis in plants is initiated by the cucurbitadienol synthase (Shibuya et al., 2004). The primary cucurbitacins synthesized are cucurbitacins E and B that possess an acetyl function at C25 (Fig. 1) (Gry et al., 2006). The other cucurbitacins are produced due to several metabolic reactions as hydrogenation by cucurbitacin Δ23-reductase, deacetylation by cucurbitacin acetylesterases, hydroxylation, dehydrogenation and isomerization reactions (Dirr et al., 1986, Gry et al., 2006, Schabort and Teijema, 1968). Those reactions lead to more than 20 different species of cucurbitacins that differ from each other by their hydroxylation at C-2, -3, -19, -24, the presence of a double bond between C-1 and C-2 or between C-23 and C-24, the acetylation of the C-25 hydroxyl group and the presence of a ketone function at C-3 (Chen et al., 2005).
Cucurbitacins are of great interest for their pharmacological use because of their numerous biological activities. They show cytotoxicity toward a large number of human cancer cell lines such as human colon, breast, lung, central nervous system, prostate, nasopharynx (Balliano et al., 1983, Chen et al., 2005, Duncan et al., 1996, Jayaprakasam et al., 2003) by inhibiting the Jak/Stat3 pathway (Blaskovich et al., 2003, Sun et al., 2005) or by disrupting the actin and vimentin networks in cytoskeleton (Duncan et al., 1996). They are also known for their anti-inflammatory, anti-pyretic, analgesic, hepato-protective, anti-HIV and antioxidants activities (Chen et al., 2005, Escandell et al., 2007, Jayaprakasam et al., 2003, Peters et al., 1999, Siqueira et al., 2007).
Cucurbitacins E, D and I are the most studied cucurbitacins as they are among the most abundant in plants. Cucurbitacin E is the acetylated form of cucurbitacin I (Fig. 1) (Chen et al., 2005). So far, two studies have been reported, only focused on the metabolism of cucurbitacins E and I. The first study reported that cucurbitacins E and I were rapidly metabolized in S9-supernatants of rat liver, but without attempting to identify the metabolites formed (Lorenz et al., 2005). The second reported the in vitro hydrolysis of cucurbitacin E into cucurbitacin I in human plasma by paraoxonase (Saade et al., 2009). The metabolic pathway of cucurbitacins is still unclear. Therefore, it is necessary to bring additional information on the biotransformation of cucurbitacins in man. Particularly, the presence of several hydroxyl groups on the molecules suggests that they are potential substrates of UDP-glucuronosyltransferases and sulfotransferases.
In this work, a systematic comparative study of the cytotoxicity against the human bone chondrosarcoma cell lines, SW 1353 has been measured. Chondrosarcomas are rare malignant cartilage tumors divided into subgroups based on their matrix composition and cellular behavior. These tumors exhibit degradation of cartilage matrix composition and organization by displaying high water content and peripheral enchondral ossification (Murphey et al., 2003). They still have no cures, and surgery remains the main form of treatment (Herget et al., 2011). With the aim to develop new therapeutic drugs against this cancer with poor diagnosis, the cytotoxicity potency of cucurbitacins on the chondrosarcoma cell line SW 1353 has been investigated.
Section snippets
Chemicals
Cucurbitacins I, D and E were purchased from Extrasynthese (Genay Cedex, France). UDP-[U-14C]-glucuronic acid (specific activity 285 mCi/mmol) and [35S]3′-phosphoadenosine-5′-phosphosulfate (0.289 Ci/mmol) were purchased from Perkin Elmer (Courtaboeuf, France). UDP-glucuronic acid, 1-naphthol, nifedipine, 4-nitrophenol, 4-aminobiphenyl, eugenol, RS-ketoprofen, hyodeoxycholic acid, octylgallate, nicotinamide adenine dinucleotide phosphate (NADPH), cytochalasin D, phenylmethionyl sulfonylfluoride
MTT assay
The viability of the chondrosarcoma SW 1353 cell line was investigated by MTT assay after addition in the culture medium of 0, 0.1, 1, 10 and 100 μM cucurbitacins I (Fig. 2a), D (Fig. 2b) and E (Fig. 2c) for 6, 12, 24, 46 and 70 h. It was compared with that measured after cytochalasin D addition (Fig. 2d). The presence of dimethyl sulfoxide (0.1%, v/v) in the culture medium led to a 2–2.5-fold increase in cell viable number, when compared to that observed in the culture medium in which the
Discussion
Cucurbitacins are natural compounds known for their numerous potent pharmaceutical effects. They have shown cytotoxic effects on several cancer cell lines (Nakashima et al., 2010) and anti-inflammatory activities on rheumatoid arthritis (Escandell et al., 2007). These effects are mainly due to their strong inhibition of STAT3 (Signal Transducers and Activators of Transcription-3) and of IKK/NF-κB pathways leading to a decrease in the activity of key inflammatory enzymes, such as
Conclusion
In conclusion, our results show that cucurbitacins D, E and I present a potent cytotoxicity toward the chondrosarcoma SW 1353 cancer cell line and they are metabolized by conjugation reactions. More work is needed to determine the fate of these compounds in man before to consider their utilization on a therapeutic basis.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Acknowledgments
This work was supported by a CEDRE grant no. 75/2010, by Lebanese National Council for Scientific Research (Ref. 02-04-09) and by the Ligue Régionale contre le Cancer.
References (40)
- et al.
Metabolic transformations of cucurbitacins by Diabrotica Virgifera Virgifera Leconte and D. Undecimpunctata Howardi Barber
Insect Biochemistry
(1988) - et al.
Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human
Archives of Biochemistry and Biophysics
(2001) - et al.
The transformation of 10α-cucurbita-5,24-dien-3β-ol into cucurbitacin C by seedlings of Cucumis sativius
Phytochemistry
(1983) - et al.
A unified method for the assay of uridine diphosphoglucuronosyltransferase activities toward various aglycones using uridine diphospho[U-14C]glucuronic acid
Analytical Biochemistry
(1980) - et al.
Relationship between cucurbitacins reverse-phase high performance liquid chromatography hydrophobicity index and basal cytotoxicity on HepG2 cells
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
(2005) - et al.
In vitro studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
(2011) - et al.
Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells
Biochemical Pharmacology
(1996) - et al.
Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells
Leukemia Research
(2008) - et al.
Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana
Cancer Letters
(2003) - et al.
Inter-individual variability in esterases in human liver
Biochemical Pharmacology
(2007)
Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans
Gastroenterology
The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue
Biochemical Pharmacology
Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells
Bioorganic and Medicinal Chemistry Letters
Anti-inflammatory effects of the products from Wilbrandia ebracteata on carrageenan-induced pleurisy in mice
Life Sciences
Study of NADH stability using ultraviolet–visible spectrophotometric analysis and factorial design
Analytical Biochemistry
Cucurbitacin 19-hydroxylase in Cucurbita maxima
Phytochemistry
The role of cucurbitacin Δ23-reductase in the breakdown pathway of toxic bitter principles in Cucurbita maxima
Phytochemistry
Sulfation and glucuronidation of phenols: implications in coenzyme Q metabolism
Methods in Enzymology
Cucurbitadienol synthase, the first committed enzyme for cucurbitacin biosynthesis, is a distinct enzyme from cycloartenol synthase for phytosterol biosynthesis
Tetrahedron
Anti-inflammatory effects of a triterpenoid isolated from Wilbrandia ebracteata Cogn
Life Sciences
Cited by (29)
Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds
2021, European Journal of CancerCucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells
2020, Biochemistry and Biophysics ReportsCytotoxicity of cucurbitacin E from Citrullus colocynthis against multidrug-resistant cancer cells
2019, PhytomedicineCitation Excerpt :The major constituents are cucurbitacins beside other compounds such as flavonoids, alkaloids, carbohydrates, and fatty acids (Abdelwahab et al., 2011; Najafi et al., 2010). Several studies reported that CuB and CuE are the principal cucurbitacin types in the Cucurbitaceae family (Abbas et al., 2013; Gry et al., 2006; Wang et al., 2017). Under certain environmental conditions, primary cucurbitacins undergo different enzymatic reactions to form other cucurbitacin derivatives.
Bioactive profile of pumpkin: an overview on terpenoids and their health-promoting properties
2018, Current Opinion in Food ScienceDevelopment and validation of a quantification method for cucurbitacins E and I in rat plasma: Application to population pharmacokinetic studies
2017, Journal of Pharmaceutical and Biomedical AnalysisCitation Excerpt :However, the plasma concentrations of cucurbitacin I remained below the LLOQ (0.4 ng/mL plasma) in all samples collected up to 24 h after the administration of cucurbitacin E. Studies on the metabolism of cucurbitacin E in human liver microsomes and in human plasma have shown the formation of cucurbitacin I [17,16]. Saade et al. [16] suggested the participation of paraoxonase in the hydrolysis of cucurbitacin E to cucurbitacin I in human plasma.